NewsRoom Articles - Page 118 of 144 - PsychedelicNewsWire (PNW)

MondayJul 06, 2020 10:00 am

Phase 1 Clinical Trial Planned to Evaluate DMT

Mind Medicine (NEO: MMED) (OTCQB: MMEDF) (“MindMed”) recently announced that it was providing funding for a Phase 1 clinical trial aimed at evaluating the main psychotropic active ingredient dimethyltryptamine (“DMT”) found in ayahuasca. This clinical trial is slated to begin in the fourth quarter of this year. DMT occurs naturally and is the primary reason why the indigenous shamanic practitioners in the Amazon use ayahuasca in their ceremonies. However, DMT quickly triggers its psychoactive effects and these effects also wear off a lot sooner than those of other psychedelic ingredients like LSD and psilocybin. When DMT is administered as an…

ThursdayJul 02, 2020 3:45 pm

Activists Say Oregon Psilocybin Ballot Measure Obtained Enough Signatures for November Poll

Activists behind an initiative to legalize magic (psilocybin) mushrooms in Oregon for medicinal purposes have announced that they gathered a lot more than the required number of voter signatures in order for the measure to qualify for the polls in November. While Oregon’s Secretary of State hasn’t verified all those signatures, the advocates behind the “Yes on IP34” say that according to their independent audit, the campaign exceeded the minimum number of required signatures before the deadline on July 2. Their confidence may not be misplaced, given that the office of the Secretary of State had confirmed that the first…

ThursdayJul 02, 2020 10:00 am

3 Novel Ways in Treating Addiction

Approximately 40 million people in the U.S. suffer from substance abuse disorders (SAD), and the number is expected to grow as other forms of addiction, such as gambling and video games, take a bigger toll on the population. Currently, there are about eight drugs to treat addiction, and it isn’t surprising that these aren’t always helpful in treating patients since the people with SAD exhibit various symptoms which may not always respond to the existing pharmaceutical options. Consequently, there is a huge need to think outside the box and come up with novel ways to treat SAD. Here are three…

WednesdayJul 01, 2020 3:15 pm

New Poll Shows Most Canadians Support Legalizing Psilocybin for Terminally Ill Patients

A new poll conducted in June this year shows that most Canadians support the legalization of psilocybin, the active ingredient in magic mushrooms (shrooms) for the treatment of terminally ill patients. Currently, magic mushrooms are listed in Schedule III of the Controlled Drugs and Substances Act in Canada. This makes the compound inaccessible for therapeutic purposes. This categorization has remained even if a lot of research from globally respected research entities at New York University, Johns Hopkins, UCLA and Kings College London, among others, shows the irrefutable potential and safety of psychedelics in treating a variety of conditions. TheraPsil, a…

WednesdayJul 01, 2020 10:00 am

New Product Could Flip the Switch on Bad LSD Trips

When you talk to a number of people who have ever consumed magic mushrooms and other plant-based psychedelic substances, you will inevitably encounter stories of “bad trips” characterized by feelings of entrapment, mild anxiety, terror, alienation and other such unpleasant effects. The risk of these “bad trips” scares a lot of people away from using psychedelics, and one psychedelic medicine company has come up with an invention that could neutralize and stop a bad LSD trip in its tracks. Mind Medicine (NEO: MMED) (OTCQB: MMEDF) (“MindMed”), together with the Liechti Laboratory found at Basel University Hospital in Switzerland, are the…

TuesdayJun 30, 2020 3:30 pm

Psychedelic Stocks: Why Your Investment Portfolio Should Be Teeming With Them

This may sound unbelievable, but, despite the raging COVID-19 pandemic, great investment opportunities are still out there. By investment, we are not referring to companies which specialize in bulk-packaging toilet paper or churning out millions of gallons of sanitizer. Psychedelic medicine stocks are what we are talking about, and here are some compelling reasons why your investment portfolio needs to have these medicines. You’d Be Getting in Early Lots of people who invested in marijuana stocks are regretting their decision for one key reason; they joined the fray late in the game when marijuana stocks had nearly peaked, and the…

TuesdayJun 30, 2020 10:00 am

Danish Researchers Discover Novel Way of Making Psilocybin from Kitchen Ingredient

Just as the immense potential of psilocybin is being recognized and accepted by the scientific community, researchers are already hard at work looking for new ways of making the chemical without having to rely on growing magic mushrooms on a large scale. To this end, a team of Danish researchers appears to have found an easy way to make this chemical by using yeast. The DTU Biosustain scientists discovered that a common species of yeast used in winemaking, brewing and baking can act as a host for psilocybin when this yeast is subjected to a process that the researchers refer…

MondayJun 29, 2020 4:30 pm

3 Key Reasons Why Psychedelics Could Upset Big Pharmaceuticals

The early results from clinical studies on psychedelics have shown that these substances have immense potential to treat a number of mental disorders, and this has in turn triggered a major shift in public perception regarding these substances. One industry that is likely to follow these developments with a lot of interest is the pharmaceutical industry. Several reasons could explain why they have more than a casual interest in psychedelics. Psychedelics Could Cure Rather Than Provide Temporary Relief The existing pharmaceutical medications for mental disorders offer temporary relief at best, and have no effect in lots of cases. Additionally, the…

MondayJun 29, 2020 10:00 am

Why Psychedelics Stocks May Currently Be Undervalued

Even before the COVID-19 pandemic sucker-punched the stock market, it was rather hard for investors to find worthwhile investment opportunities. It was therefore just a matter of time before a market correction occurred, and the coronavirus outbreak provided the trigger for this correction. However, as the markets nosedive, experienced investors know that such a correction presents new opportunities. One industry where there is huge potential for investors is the psychedelics sector. Just like the marijuana industry, psychedelics represent a novel way to treat not just mental but also physical ailments. However, that may be where the comparisons stop between those…

FridayJun 26, 2020 4:00 pm

Psychedelics-Centered Clinics: What You Need to Know

As a potential investor in psychedelics, you may be wondering how firms will generate meaningful revenues from this industry given that the pharmaceutical and biotech industries are investment-heavy. Well, the answer to this question seems to be that psychedelics companies that operate treatment clinics stand a higher chance of having a revenue edge over those that don’t have clinics. Clinics are the logical way to go for psychedelic companies since, as anyone who has ever tried psychedelics will tell you, the psychedelic experience is a profound one that takes an individual on a journey into their own selves so that…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050